Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO)

This study is looking into a new treatment called faricimab, also known as Vabysmo, for an eye condition called polypoidal choroidal vasculopathy, or PCV. PCV affects the back of the eye, causing abnormal blood vessels to grow. These vessels can leak fluid and blood, which can lead to blurred vision or even vision loss. While we have treatments for PCV, such as other eye injections, doctors are still trying to find better ways to manage the condition, especially for white patients where PCV might be underdiagnosed.

Faricimab is a newer medication that doctors hope will be more effective and require less frequent injections than current treatments. This study specifically wants to see if faricimab improves vision in white patients with PCV and how long these benefits last. It also wants to check if the treatment is safe and well-tolerated. The current treatments, while helpful, often require many doctor visits for injections, which can be difficult for patients. If faricimab works well and lasts longer, it could mean fewer visits and less burden for people living with PCV.

Researchers are focusing on white patients because PCV seems to affect different groups of people in slightly different ways. By understanding how faricimab works for this specific group, they can ensure that the treatment is effective across different populations. The ultimate goal is to find a treatment that helps to better control PCV, prevent further vision loss, and improve the quality of life for patients.